Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human Fc gamma RIIIA / CD16a (V176) Protein, HSA,His Tag (MALS & BLI verified), 100 µg  

Recombinant Human Fc gamma RIIIA / CD16a (V176) Protein, HSA,His Tag (MALS & BLI verified), 100 µg

Recombinant Human Fc gamma RIIIA / CD16a (V176) Protein, AA Gly 17 - Gln 208, expressed from human 293 cells (HEK293), HSA Tag, His Tag (MALS & BLI verified)

Synonym
recombinant, human, protein, FCGR3A, CD16A, FCG3, FCGR3, IGFR3

More details

CDA-H52S1-100

Availability: within 7 days

364,00 €

Background
CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner. CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages. CD16a antigen is also known as Low affinity immunoglobulin gamma Fc region receptor III-A, Fc-gamma RIII-alpha. CD16b is a low-affinity, GPI-linked receptor expressed by neutrophils and eosinophils, whereas CD16a is an intermediate affinity polypeptide-anchored transmembrane glycoprotein expressed natural killer cells, macrophages, subpopulation of T-cells, immature thymocytes and placentaltrophoblasts.CD16a is involved in phagocytosis, secretion of enzymes and inflammatory mediators, antibody­dependent cytotoxicity and clearance of immune complexes. Aberrant expression or mutations of CD16a is implicated in susceptibility to recurrent viral infections, systemic lupus erythematosus, and alloimmune neonatal neutropenia.

Source
Recombinant Human CD16a (V176), HSA,His Tag (CDA-H52S1) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # P08637-1(F176V)).
Predicted N-terminus: Gly 17

Molecular Characterization
This protein carries a HSA tag at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 90.6 kDa. The protein migrates as 90-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Post-HDX Deglycosylation of Fc Gamma Receptor IIIa Glycoprotein Enables HDX Characterization of Its Binding Interface with IgG"
Wagner, Huang, Liu et al
J Am Soc Mass Spectrom (2021) 32 (7), 1638-1643
(2) "Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab"
Hayes, Frostell, Karlsson et al
Mol Cell Proteomics (2017) 16 (10), 1770-1788
(3) "Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype"
Congy-Jolivet, Bolzec, Ternant et al
Cancer Res (2008) 68 (4), 976-80
Showing 1-3 of 4 papers.